Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE4
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
- Status
- COMPLETED
- Phase
- PHASE3
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE2
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
GO-203-2C + Bortezomib For Relapsed Or Refractory MM
- Status
- WITHDRAWN
- Phase
- PHASE1
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE4
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
- Status
- COMPLETED
- Phase
- N/A
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Immune Modulation Therapy for Pompe Disease
- Status
- UNKNOWN
- Phase
- PHASE4
Quantitating the Impact of Plerixafor
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation
- Status
- COMPLETED
- Phase
- PHASE1
Belimumab Impacting Transplant Eligibility
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2